| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Counted by filing, the last 12 months brought 1 open-market purchase by 1 insider worth about $250K and 5 sales by 2 insiders worth about $592K. The 12 months before that brought 1 open-market purchase by 1 insider worth about $5.5M and no sales.
All 5 sales in the last 12 months were made under a Rule 10b5-1 trading plan set up in advance.
The largest open-market purchase in the last two years was 6,306,127 shares by Mona Ashiya (Director) at an average $0.87 on August 25, 2025, about $5.5M. Twelve months later STTK was up 711%.
The most recent purchase was by Clay B Siegall (Director) on June 9, 2026.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 318.6K | $1.74M | - | |
| CFO | 292.3K | $1.60M | - | |
| Other | 136.2K | $745.1K | - | |
| CEO | 122.2K | $668.6K | - | |
| Other | 98.5K | $539.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | Abhinav A. Shukla45 | Chief Technical Officer | Sale+OE10b5-1 | 410 | $7.01 | $2,874.10 | -0.5% | -3.3% | - | |
| Jul 1, 2026 | Abhinav A. Shukla45 | Chief Technical Officer | Sale+OE10b5-1 | 23,465 | $7.08 | $166,131.20 | -21.4% | +0.5% | - | |
| Jun 30, 2026 | Arundathy N. Pandite | Chief Medical Officer | Sell10b5-1 | 30,000 | $7.01 | $210,300.00 | -18.0% | -7.3% | - | |
| Jun 9, 2026 | Clay B Siegall77 | Director | Buy | 62,500 | $4.00 | $250,000.00 | +24.4% | +52.2% | - | |
| May 12, 2026 | Abhinav A. Shukla45 | Chief Technical Officer | Sale+OE10b5-1 | 2,032 | $7.01 | $14,244.32 | -2.4% | +7.9% | - | |
| May 12, 2026 | Arundathy N. Pandite | Chief Medical Officer | Sell10b5-1 | 30,000 | $6.61 | $198,300.00 | -15.3% | +7.9% | - | |
| Aug 25, 2025 | Mona Ashiya66 | Director | Buy | 6,306,127 | $0.87 | $5,471,826.40 | -120.0% | +107.3% | +711.1% | |
| Aug 25, 2025 | Orbimed Advisors LLC68 | Director | Buy | 6,306,127 | $0.87 | $5,471,826.40 | -120.0% | +107.3% | +711.1% | |
| Dec 4, 2024 | Redmile Group, LLC48 | Director, 10% Owner | Sell | 133,371 | $1.25 | $166,713.75 | -2.4% | -1.6% | +137.6% | |
| Dec 4, 2024 | Redmile Group, LLC48 | Director, 10% Owner | Buy | 133,371 | $1.25 | $166,713.75 | +2.5% | -1.6% | +137.6% |